KSL11h
Lilly's weight-loss treatment Zepbound becomes first FDA-approved drug for sleep apnea
"Too often, obstructive sleep apnea is brushed off as 'just snoring' — but it's ... Zepbound and Lilly's widely used diabetes ...
Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Hosted on MSN16h
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
24/7 Wall St17h
Eli Lilly (LLY) Stock Price Prediction and Forecast 2025-2030
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...
Northwest Naturals raw pet food tied to bird flu in cat; recall issued
The recall, according to a news release published Wednesday, involves Northwest Naturals' Feline Turkey Recipe raw frozen pet ...
FDA approves weight-loss drug Zepbound to treat sleep apnea
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
McKnight's Long-Term Care News23h
FDA approves Zepbound for sleep apnea in patients with obesity
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).